What is Cofactor Genomics?
Cofactor Genomics is a pioneer in the field of RNA-Seq technology, specifically engineered to enhance predictive diagnostics within the oncology sector. The company's flagship innovation, the OncoPrism assay, serves as a critical tool for medical oncologists and pathologists by accurately predicting patient responses to immunotherapy. By leveraging multidimensional biomarkers, the firm provides a sophisticated analytical framework that moves beyond traditional diagnostic limitations.
Currently integrated into clinical workflows across more than 24 healthcare systems, Cofactor Genomics is redefining the standard of care in immune-oncology. Its market position is defined by a unique synthesis of data science and molecular biology, enabling a more personalized approach to treatment selection. This focus on precision medicine positions the company as a vital partner for clinical researchers aiming to improve patient survival rates through data-driven therapeutic matching.
How much funding has Cofactor Genomics raised?
Cofactor Genomics has raised a total of $21.5M across 5 funding rounds:
Other Financing Round
$2.6M
Other Financing Round
$120K
Series A
$18M
Debt
$350K
Debt
$424K
Other Financing Round (2015): $2.6M with participation from BioGenerator, Paul Buchheit, 7percent Ventures, Data Collective, TenOneTen, AME Cloud, Jude Gomila, and David Lee
Other Financing Round (2015): $120K led by Y Combinator
Series A (2017): $18M supported by Ascension Ventures, Data Collective, Stanford, Y Combinator, Menlo Ventures, Wilson Sonsini Goodrich & Rosati, and iSelect Fund Management
Debt (2020): $350K featuring PPP
Debt (2021): $424K backed by PPP
Key Investors in Cofactor Genomics
Ascension Ventures
A strategic healthcare venture firm backed by leading non-profit health systems, focusing on investments that transform the healthcare industry and enhance patient experiences.
Data Collective
A venture firm dedicated to supporting technology that helps organizations find, understand, and leverage data to advance knowledge and education.
AME Cloud Ventures
A venture fund led by Jerry Yang that focuses on infrastructure and value chains built around data, supporting companies that gather or create unique data assets.
What's next for Cofactor Genomics?
Looking ahead, the strategic deployment of the $424K will likely accelerate the expansion of Cofactor Genomics' clinical trial footprint and the broader adoption of its diagnostic assays. As the company continues to refine its multidimensional biomarker technology, the focus will shift toward deepening its integration within major hospital networks and enhancing the predictive accuracy of its platform.
The firm is well-positioned to capitalize on the growing demand for precision diagnostics in the immunotherapy market. By maintaining its commitment to rigorous clinical validation and strategic partnerships, Cofactor Genomics is poised to influence the future of oncology, potentially setting new benchmarks for how genomic data informs clinical decision-making and patient management strategies.
